BERKELEY HEIGHTS, NJ- December 31, 2002 -
Genta Incorporated (Nasdaq: GNTA) today announced its participation
at the JP Morgan H&Q Healthcare Conference in San Francisco,
CA. Raymond P. Warrell, Jr., M.D., Chairman and Chief Executive
Officer, will make a presentation on Monday, January 6, 2003 at
2:30 p.m. PST that will feature clinical overviews and updates on
the Company's Genasense
TM
(oblimersen sodium) and Ganite. (gallium nitrate)
programs.
The webcast of the presentation can be accessed via
the web through Genta's investor site at:
http://genta.com/investor/events.htm
. A replay will be available for 30 days following the
presentation.
About Genasense
Genasense works by inhibiting the production of
Bcl-2, a protein made by cancer cells that is thought to block
chemotherapy-induced cell death. By reducing the amount of Bcl-2 in
cancer cells, Genasense may enhance the effectiveness of current
anticancer treatments. Genasense is currently in multiple,
late-stage, randomized clinical trials in patients with malignant
melanoma, multiple myeloma, chronic lymphocytic leukemia (CLL) and
non-small cell lung cancer.
About Ganite
Ganite (gallium nitrate injection) has received
regulatory approval in the U.S. and Canada as an intravenous
treatment for patients with hypercalcemia who are unresponsive to
hydration. Genta plans to market the drug by itself in the U.S.,
pending submission and approval by FDA of certain regulatory
amendments to the existing NDA. Published reports have also
suggested that the drug has direct antitumor activity. Genta has
filed an Investigational New Drug (IND) exemption with the Oncology
Division at FDA for the clinical evaluation of gallium nitrate, and
the Company has an ongoing Phase 2b clinical trial in patients with
non-Hodgkin's lymphoma. Genta currently plans to seek one or more
additional registrations for the use of Ganite as an anticancer
agent.
About Genta
Genta Incorporated is a biopharmaceutical company
with a diversified product portfolio that is focused on anticancer
therapy. The Company's research platform is anchored by
oligonucleotide chemistry, particularly applications of antisense
and decoy aptamer technology. GenasenseTM, the Company"s lead
compound, is being developed in collaboration with Aventis and is
currently undergoing late-stage, Phase 3 clinical testing in
several clinical indications. Genta's pipeline also comprises a
portfolio of small molecules, including gallium-containing
compounds and Androgenics compounds for prostate cancer. For more
information about Genta, please visit our website at:
http://www.genta.com/
The statements contained in this press release and the
webcast to follow that are not historical are forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, including statements regarding
the expectations, beliefs, intentions or strategies regarding the
future. Without limiting the foregoing, the words
``anticipates,"" ``believes,"" ``expects,"" ``intends,"" ``may""
and ``plans"" and similar expressions are intended to identify
forward-looking statements. The Company intends that all
forward-looking statements be subject to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements reflect the Company"s
views as of the date they are made with respect to future events,
but are subject to many risks and uncertainties, which could
cause the actual results of the Company to differ materially from
any future results expressed or implied by such forward-looking
statements. For example, the results obtained in pre-clinical or
clinical studies may not be indicative of results that will be
obtained in future clinical trials, and delays in the initiation
or completion of clinical trials may occur as a result of many
factors. Further examples of such risks and uncertainties also
include, but are not limited to: the obtaining of sufficient
financing to maintain the Company"s planned operations; timely
development, receipt of necessary regulatory approvals, and
acceptance of new products; the successful application of the
Company"s technology to produce new products; the obtaining of
proprietary protection for any such technology and products; the
impact of competitive products and pricing and reimbursement
policies; and changing market conditions. The Company does not
undertake to update forward-looking statements. Although the
Company believes that the forward-looking statements contained
herein are reasonable, it can give no assurances that the
Company"s expectations are correct. All forward looking
statements are expressly qualified in their entirety by this
cautionary statement and other factors detailed in the Company"s
reports filed with the Securities and Exchange Commission.
SOURCE: Genta Incorporated
